Biotech Business - March 28, 2023
Salipro publishes results from collaboration with AstraZeneca
The study describes a novel method to directly extract membrane proteins from cells into lipid Salipro nanoparticles, enabling structure-function analysis using surface plasmon resonance (SPR) and cryo-electron microscopy (cryo-EM) for challenging drug targets. For this study, the teams leveraged GeneArt Gene-to-Protein Services, part of Thermo Fisher Scientific, for protein production with structure determination support from […]
Acquisition - March 27, 2023
Pharm Assist is now part of LINK Medical
LINK Medical has announced the integration of Pharm Assist into the LINK Medical family. “We are very excited to have Pharm Assist integrate with our network of expert teams, especially strengthening our already robust regulatory group making us very unique in our industry. Our Regulatory team across the Nordics now has over 60 specialists, including […]
Agreement - March 27, 2023
Orion and Bayer expand clinical development program
Orion and Bayer further expand the global clinical development program for the oral androgen receptor inhibitor (ARi) darolutamide in prostate cancer. The new Phase III clinical study, ARASTEP, will investigate the efficacy of darolutamide plus androgen deprivation therapy (ADT) versus ADT alone in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence (BCR) who have […]
New Market - March 27, 2023
AstraZeneca’s Calquence granted first regulatory approval in China
Calquence, a next generation, selective Bruton’s tyrosine kinase (BTK) inhibitor, has been conditionally approved in China for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. This is the first approved indication for Calquence in China. “This approval for Calquence offers people living with mantle cell […]
CDMO - March 23, 2023
Biovian and Remedium collaborate on AAV gene therapy
The agreement covers Remedium’s lead candidate, a disease-modifying treatment for Osteoarthritis (OA) under the name RMD 1101. Biovian has agreed to include Remedium’s lead candidate in Biovian’s AAV manufacturing platform development program. Biovian’s second-generation AAV platform will be built around a selected high-productivity and state-of-the-art quality suspension-based HEK293 cell line, with full scalability to 200L […]
Biotech Business - March 22, 2023
Aqilion to recieve 20.1 million SEK
In order to strengthen the company’s liquidity and to ensure the continued development of the company’s pipeline, on July 27, 2022 the Aqilion Board of Directors decided on to carry out an issue with priority for existing owners. The issue was carried out during the third quarter of 2022 as an issue of units, which […]
